Clinical Trial Update: Short-course Radiotherapy Combined With Serplulimab and Chemotherapy as Neoadjuvant Treatment for Resectable ESCC [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating short-course radiotherapy in combination with serplulimab and chemotherapy as neoadjuvant therapy for resectable esophageal …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Serplulimab (serplulimab)

Snippet

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Conditions: Esophageal Squamous Cell Carcinoma (ESCC) | Phase 2 | Status: NOT_YET_RECRUITING